May 6th 2024
Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
ICIs Demonstrate Longer TTNT and OS Over Taxane Treatment in mCRPC
April 20th 2022A recent study looked into where time-to-next therapy and overall survival with immune checkpoint inhibitors were longer compared with taxane therapy, in patients with metastatic castration-resistant prostate cancer.
Read More
Choudhury Discusses Sequencing of Therapy in Metastatic Castration-Resistant Prostate Cancer
April 16th 2022During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed the CARD trial of cabazitaxel and the VISION trial of lutetium-177 for patients with metastatic castration-resistant prostate cancer.
Read More
Potential Use of Lu 177 Vipivotide Tetraxetan in Non-VISION Prostate Cancer Settings
April 15th 2022Scott Tagawa, MD, MS, FACP, discusses other prostate cancer settings besides metastatic CRPC where Lu 177 vipivotide tetraxetan could potentially be useful, and touches on ongoing clinical trials in these settings.
Watch
gLOH-High May Be a Marker for Improved Response to Talazoparib in mCRPC
April 12th 2022Results from a post-hoc exploratory analysis of the TALAPRO-1 study signal that high genomic loss of heterozygosity may be assiciated with enhanced response to talazoparib in patients with metastatic castration-resistant prostate cancer.
Read More
Overcoming Disparities in Prostate Cancer Beginning With Patients Insured by Medicaid
April 8th 2022In an interview with Targeted Oncology, Shawn Dason, MD, discussed existing disparities in prostate cancer, the impact of the COVID-19 pandemic on the issue, and achieving health equity for patients with prostate cancer in the future.
Read More
FDA Approves Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
March 23rd 2022The FDA has granted approval to the agent formerly known as 177Lu-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post-taxane-based chemotherapy setting.
Read More
FDA Approval Sought for Darolutamide/Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
March 9th 2022A supplemental new drug application seeking FDA approval for darolutamide and docetaxel for the treatment of patient with metastatic hormone-sensitive prostate cancer has been submitted.
Read More